StockData
Karyopharm Therapeutics Inc. logo

Karyopharm Therapeutics Inc. (KPTI) stock

KPTINasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as KPTIQ
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 1/30
$0.04−0.01 (-20.00%)

Close on Nov 9, 2026Market cap $1.16KP/E –Yield –

Karyopharm Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Karyopharm Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -153.3%. For fiscal 2025 it was -134.2%, against -52.6% the year before. The highest annual figure on record is -52.6% in fiscal 2024.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-134.2%−81.6
FY2024Dec 31, 2024-52.6%+45.4
FY2023Dec 31, 2023-98.0%+7.2
FY2022Dec 31, 2022-105.2%−46.1
FY2021Dec 31, 2021-59.1%+122.5
FY2020Dec 31, 2020-181.6%+306.5
FY2019Dec 31, 2019-488.1%+100.0
FY2018Dec 31, 2018-588.1%+7448.3
FY2017Dec 31, 2017-8036.4%+63117.5
FY2016Dec 31, 2016-71153.9%−23881.5
FY2015Dec 31, 2015-47272.4%−14182.0
FY2014Dec 31, 2014-33090.4%−24318.6
FY2013Dec 31, 2013-8771.8%−6265.8
FY2012Dec 31, 2012-2506.0%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-200.5%−102.3
Q1 FY2026Mar 31, 2026-63.9%+14.3
Q4 FY2025Dec 31, 2025-299.9%−199.1
Q3 FY2025Sep 30, 2025-75.2%+7.5
Q2 FY2025Jun 30, 2025-98.2%−153.8
Q1 FY2025Mar 31, 2025-78.2%+34.6
Q4 FY2024Dec 31, 2024-100.8%+23.2
Q3 FY2024Sep 30, 2024-82.7%+13.1
Q2 FY2024Jun 30, 202455.6%+142.4
Q1 FY2024Mar 31, 2024-112.8%−24.6
Q4 FY2023Dec 31, 2023-124.0%−9.3
Q3 FY2023Sep 30, 2023-95.8%+4.7
Q2 FY2023Jun 30, 2023-86.8%+36.8
Q1 FY2023Mar 31, 2023-88.2%−1.3
Q4 FY2022Dec 31, 2022-114.7%−145.3
Q3 FY2022Sep 30, 2022-100.5%+37.0
Q2 FY2022Jun 30, 2022-123.6%+113.4
Q1 FY2022Mar 31, 2022-86.8%+160.0
Q4 FY2021Dec 31, 202130.7%+154.4
Q3 FY2021Sep 30, 2021-137.5%+113.3
Q2 FY2021Jun 30, 2021-237.1%−98.6
Q1 FY2021Mar 31, 2021-246.8%+45.0
Q4 FY2020Dec 31, 2020-123.7%+145.1
Q3 FY2020Sep 30, 2020-250.8%+63.8
Q2 FY2020Jun 30, 2020-138.5%+318.8
Q1 FY2020Mar 31, 2020-291.8%+42392.7
Q4 FY2019Dec 31, 2019-268.8%+27988.5
Q3 FY2019Sep 30, 2019-314.6%+19803.8
Q2 FY2019Jun 30, 2019-457.3%−288.1
Q1 FY2019Mar 31, 2019-42684.5%−42299.9
Q4 FY2018Dec 31, 2018-28257.3%−25712.3
Q3 FY2018Sep 30, 2018-20118.4%+959448.3
Q2 FY2018Jun 30, 2018-169.2%+43826.4
Q1 FY2018Mar 31, 2018-384.6%+56923.9
Q4 FY2017Dec 31, 2017-2545.0%+50423.8
Q2 FY2017Jun 30, 2017-979566.7%–
Q1 FY2017Mar 31, 2017-43995.6%–
Q4 FY2016Dec 31, 2016-57308.5%–
Q3 FY2016Sep 30, 2016-52968.8%–

More Karyopharm Therapeutics figures

See a number that looks wrong?